-
Je něco špatně v tomto záznamu ?
Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity
Trávnícek Z, Krystof V, Sipl M.
Jazyk angličtina Země Spojené státy americké
- MeSH
- chloridy farmakologie chemie MeSH
- cyklin-dependentní kinasy antagonisté a inhibitory chemie MeSH
- diferenční termická analýza MeSH
- financování organizované MeSH
- hmotnostní spektrometrie MeSH
- inhibitory enzymů farmakologie chemická syntéza chemie MeSH
- kinetin farmakologie chemie MeSH
- krystalografie rentgenová MeSH
- lidé MeSH
- ligandy MeSH
- magnetická rezonanční spektroskopie MeSH
- molekulární struktura MeSH
- nádorové buněčné linie MeSH
- organokovové sloučeniny farmakologie chemická syntéza chemie MeSH
- protinádorové látky farmakologie chemie MeSH
- puriny farmakologie chemie MeSH
- screeningové testy protinádorových léčiv MeSH
- sloučeniny zinku farmakologie chemie MeSH
- spektrofotometrie infračervená MeSH
- Check Tag
- lidé MeSH
The synthesis, characterization and biological activity of the first zinc(II) complexes with potent inhibitors of cyclin-dependent kinases (CDKs) derived from 6-benzylaminopurine are described. Based on the results following from elemental analyses, infrared, NMR and ES+MS (electrospray mass spectra in the positive ion mode) spectroscopies, conductivity data, thermal analysis and X-ray structures, the tetrahedral Zn(II) complexes of the compositions [Zn(Olo)Cl(2)](n) (1), [Zn(iprOlo)Cl(2)](n) (2), [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been prepared, where Olo=2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine (Olomoucine), iprOlo=2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (i-propyl-Olomoucine), Boh=2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine (Bohemine). The 1D-polymeric chain structure for [Zn(Olo)Cl(2)](n) (1) as well as the monomeric one for [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been revealed unambiguously by single crystal X-ray analyses. The 1D-polymeric chain of 1 consists of Zn(Olo)Cl(2) monomeric units in which the Zn(II) ion is coordinated by two chlorine atoms and one oxygen atom of the 2-hydroxyethylamino group of Olomoucine. The next monomeric unit is bonded to Zn(II) through the N7 atom of a purine ring. Thus, each of Zn(II) ions is tetrahedrally coordinated and a ZnCl(2)NO chromophore occurs in the complex 1. The complexes 3 and 4 are mononuclear species with a distorted tetrahedral arrangement of donor atoms around the Zn(II) ion with a ZnCl(3)N chromophore. The corresponding CDK inhibitor, i.e., both Boh and iprOlo, is coordinated to Zn(II) via the N7 atom of the purine ring in 3 and 4. The cytotoxicity of the zinc(II) complexes against human melanoma, sarcoma, leukaemia and carcinoma cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase. A relationship between the structure and biological activity of the complexes is also discussed.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07520029
- 003
- CZ-PrNML
- 005
- 20111210130959.0
- 008
- 090325s2006 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Trávníček, Zdeněk, $d 1964- $7 ola2004209199
- 245 10
- $a Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity / $c Trávnícek Z, Krystof V, Sipl M.
- 314 __
- $a Department of Inorganic Chemistry, Palacký University, Krízkovského 10, CZ-771 47 Olomouc, Czech Republic. trav@aix.upol.cz
- 520 9_
- $a The synthesis, characterization and biological activity of the first zinc(II) complexes with potent inhibitors of cyclin-dependent kinases (CDKs) derived from 6-benzylaminopurine are described. Based on the results following from elemental analyses, infrared, NMR and ES+MS (electrospray mass spectra in the positive ion mode) spectroscopies, conductivity data, thermal analysis and X-ray structures, the tetrahedral Zn(II) complexes of the compositions [Zn(Olo)Cl(2)](n) (1), [Zn(iprOlo)Cl(2)](n) (2), [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been prepared, where Olo=2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine (Olomoucine), iprOlo=2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (i-propyl-Olomoucine), Boh=2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine (Bohemine). The 1D-polymeric chain structure for [Zn(Olo)Cl(2)](n) (1) as well as the monomeric one for [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been revealed unambiguously by single crystal X-ray analyses. The 1D-polymeric chain of 1 consists of Zn(Olo)Cl(2) monomeric units in which the Zn(II) ion is coordinated by two chlorine atoms and one oxygen atom of the 2-hydroxyethylamino group of Olomoucine. The next monomeric unit is bonded to Zn(II) through the N7 atom of a purine ring. Thus, each of Zn(II) ions is tetrahedrally coordinated and a ZnCl(2)NO chromophore occurs in the complex 1. The complexes 3 and 4 are mononuclear species with a distorted tetrahedral arrangement of donor atoms around the Zn(II) ion with a ZnCl(3)N chromophore. The corresponding CDK inhibitor, i.e., both Boh and iprOlo, is coordinated to Zn(II) via the N7 atom of the purine ring in 3 and 4. The cytotoxicity of the zinc(II) complexes against human melanoma, sarcoma, leukaemia and carcinoma cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase. A relationship between the structure and biological activity of the complexes is also discussed.
- 650 _2
- $a protinádorové látky $x farmakologie $x chemie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a chloridy $x farmakologie $x chemie $7 D002712
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a cyklin-dependentní kinasy $x antagonisté a inhibitory $x chemie $7 D018844
- 650 _2
- $a diferenční termická analýza $7 D004055
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a inhibitory enzymů $x farmakologie $x chemická syntéza $x chemie $7 D004791
- 650 _2
- $a kinetin $x farmakologie $x chemie $7 D007701
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a hmotnostní spektrometrie $7 D013058
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a organokovové sloučeniny $x farmakologie $x chemická syntéza $x chemie $7 D009942
- 650 _2
- $a puriny $x farmakologie $x chemie $7 D011687
- 650 _2
- $a spektrofotometrie infračervená $7 D013055
- 650 _2
- $a sloučeniny zinku $x farmakologie $x chemie $7 D017967
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Kryštof, Vladimír, $d 1973- $7 xx0097406
- 700 1_
- $a Šipl, Michal. $7 xx0222464
- 773 0_
- $w MED00006646 $t Journal of inorganic biochemistry $g Roč. 100, č. 2 (2006), s. 214-225 $x 0162-0134
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090325104238 $b ABA008
- 991 __
- $a 20090630141656 $b ABA008
- 999 __
- $a ok $b bmc $g 637833 $s 490629
- BAS __
- $a 3
- BMC __
- $a 2006 $b 100 $c 2 $d 214-225 $i 0162-0134 $m Journal of inorganic biochemistry $x MED00006646
- LZP __
- $a 2009-B1/dkme